The solid tumour therapy developer secured $21.9m from investors including Dai-ichi Life, Binex, Bigen and Shibuya Kogyo.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Renovacor reaches reverse merger deal
The Novartis-backed gene therapy developer will merge with Chardan Healthcare Acquisition 2 Corp and take a New York Stock Exchange listing.
Inflammatix invites OSF to $102m series D
OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.
StrideBio strikes series B deal
Novo co-led an $81.5m round for the gene therapy developer that included Sarepta Therapeutics, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.
A shining beacon in the dark
Where do you begin to summarise a year that has been the most challenging on a global scale in living memory?
Neophore negotiates $21m series B
Astellas Venture Management is among the new investors in the cancer immunotherapy developer, which was spun off by PhoreMost four years ago.
Quench Bio ends operations
Quench Bio will wind down after its protein target proved undruggable and will return capital to investors including AbbVie Ventures.
Starling makes $377m series D deposit
JTC Group-backed mobile financial services provider Starling Bank has reached a unicorn valuation with a $377m series D round led by Fidelity.
Nydig mines insurers in $200m round
MassMutual and New York Life are among the investors that co-led a $200m funding round for the Bitcoin-focused technology and services provider.
Tidal rides acquisition wave to Square
Square will purchase a majority stake in music streaming platform Tidal for $297m, four years after SoftBank subsidiary Sprint paid $200m for a 33% stake.
Hippo to hop onto NYSE
The insurer is set for a reverse merger with Reinvent Technology Partners Z to list on the New York Stock Exchange at a valuation of $5bn.
Coursera to class as public company
Seek Group, Times Internet and Laureate Education are all in line for exits when the Stanford University online education spinout lists on the New York Stock Exchange.
Ascension rises to $285m opportunity
Ascension Ventures has closed its fifth fund at $285m with the backing of 13 health systems.
Caribou Biosciences clinches $115m
Heritage Medical Systems and AbbVie Ventures took part in genome editing technology developer Caribou Biosciences’ first funding round in five years.